IC
INMB icon

Ikarian Capital’s INmune Bio INMB Stock Holding History

Ikarian Capital’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,632
Closed -$517K – 216
2021
Q3 		$517K Sell
26,632
-120,251
-82% -$2.32M 0.04% 186
2021
Q2 		$2.58M Sell
146,883
-86,693
-37% -$1.17M 0.21% 114
2021
Q1 		$2.77M Buy
233,576
+16,008
+7% +$288K 0.09% 177
2020
Q4 		$3.75M Buy
+217,568
New +$2.05M 0.17% 112

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital's INMB Position: Q4 2021 in Review

Ikarian Capital sold out of INmune Bio (INMB) in Q4 2021, closing a stake of 26,632 shares — an estimated $517K sold.

Ikarian Capital first reported a position in INMB in Q4 2020 and held it in 4 quarters. The position peaked at $3.75M in Q4 2020. 43 funds tracked by Wall St. Rank hold INMB as of Q4 2021.

  • Ikarian Capital reported no remaining INmune Bio position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 26,632 INmune Bio shares in Q4 2021, an estimated $517K.
  • Ikarian Capital first reported a position in INmune Bio in Q4 2020 and held it in 4 quarters.
  • Ikarian Capital's INmune Bio position peaked at $3.75M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held INmune Bio as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.